XML 69 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration and License Agreements - Astellas Pharma Inc - Additional Information (Details)
$ in Thousands
Mar. 23, 2020
USD ($)
Target
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue   $ 301,326 $ 284,760 $ 318,707
Astellas Pharma Inc.        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue   44,500    
Collaboration and License Agreement | Astellas Pharma Inc.        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Number of targets selected | Target 1      
Number of additional collaboration target | Target 3      
Upfront payment received $ 80,000      
Total transaction price 103,200      
Research and development service fees 23,200      
Deferred revenue   44,500 60,300  
Amount due from customer   $ 1,000 $ 800  
Collaboration and License Agreement | Astellas Pharma Inc. | Additional Contingent Payments        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Contingent milestone payments receivable $ 900,000      
Collaboration and License Agreement | Astellas Pharma Inc. | Maximum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Number of targets | Target 4      
Right to expand the number of additional collaboration target | Target 5      
Contingent milestone payments receivable $ 1,600,000      
Collaboration and License Agreement | Astellas Pharma Inc. | Minimum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Right to expand the number of additional collaboration target | Target 3